Russia Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Russia Pharmaceuticals and Healthcare Report

Russia Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Russia Pharmaceuticals and Healthcare Report
Published Jun 11, 2016
89 pages — Published Jun 11, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

Significant macro risks persist, such as increased government interference in business, the revision of earlier privatisations and corruption, particularly at regional and local levels and currency volatility. The enforcement of patent laws and other regulations will likely remain weak, while the courts are a costly and unreliable last resort. ...The enforcement of patent laws and other regulations will likely remain weak, while the courts are a costly and unreliable last resort. Plans designed to increase the share of domestically produced pharmaceuticals will continue to drive the rising state control over the sector. Tensions with Western powers threaten to spill over into tit-for-tat sanctions or trade restrictions on imported goods. ...Tensions with Western powers threaten to spill over into tit-for-tat sanctions or trade restrictions on imported goods. Measures to increase generic prescribing will increase the threat from cheap copycat drugs.

...In May ----, the Federal Antimonopoly Service (FAS) reported that Russian drugmakers were slashing the production of drugs on the Vital and Essential Medicines List due to the current economic recession and excessive pricing controls. According to the FAS, a total of --- drugs priced at or below RUB-- (USD-.--) have been removed from production, with another --- expected to follow suit. In April ----, the Kremlin and the FAS were considering amendments to the Russian Civil Code with respect to drug manufacturing. The government wants to allow domestic firms to produce foreign drugs without the permission of the patent holder. ...The government wants to allow domestic firms to produce foreign drugs without the permission of the patent holder.

...BMI View: Russia s healthcare market is in a precarious position due to a severe lack of funding and an escalating burden of disease. The country s economic recession will see further pressure placed on the population for provision of care. ...

  
Source:
Document ID
1748-2135
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Russia Pharmaceuticals and Healthcare Report" Jun 11, 2016. Alacra Store. Dec 10, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Russia-Pharmaceuticals-and-Healthcare-Report-2026-298>
  
APA:
Business Monitor International - Industry Reports. (2016). Russia Pharmaceuticals and Healthcare Report Jun 11, 2016. New York, NY: Alacra Store. Retrieved Dec 10, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Russia-Pharmaceuticals-and-Healthcare-Report-2026-298>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.